0010">Patients were randomly allocated to 40 0;Gy/15 fractions (F)/3-weeks, 27 0;Gy/5F/1-week or 26 0;Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4 0;weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4 0;weeks after completion.
0015">190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40 0;Gy/15F 6/44 (13.6%); 27 0;Gy/5F 5/51 (9.8%); 26 0;Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40 0;Gy/15F 0/43; 27 0;Gy/5F 1/41 (2.4%); 26 0;Gy/5F 0/53.
0020">Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.